Ortega-Cuartiella Alexis
Ad Astra Clinic® Medical Director and Founder, Cl. Doctor Roux 67, Bajo. Barcelona, Spain, International Society for Stem Cell Applications: Platinum Member, Real Instituto Alfonso XIII: Academician.
Int J Trichology. 2023 Sep-Oct;15(5):173-182. doi: 10.4103/ijt.ijt_3_21. Epub 2024 Jul 11.
Androgenic alopecia (AGA) and alopecia areata (AA) are two highly prevalent conditions, affecting both men and women of a wide range of ages, which strongly impact their quality of life and self-esteem. Both pathologies are deemed to be reversible, although conventional therapies have shown limited scope and efficacy. New therapeutic approaches, focusing on the degenerative changes that take place in the hair follicle, are needed to achieve better outcomes. For instance, adipose-derived stem cells (ADSC), abundant and easy to obtain, hold great potential in follicular regeneration. ADSCs can be isolated as stromal vascular fraction (SVF) by the enzymatic digestion of the lipoaspirate or as nanofat by the mechanical breakdown of adipocytes. In addition, commercial preparations of the conditioned medium of the ADSCs secretome (ADSC-conditionate medium [CM]) have entered the market as an appealing alternative because of their comparatively lower cost and accessibility. A search was conducted, crossing relevant terms, on PubMed Central and Google Scholar. Criteria for inclusion were studies in the past 10 years on humans with AGA or AA, where either SVF, nanofat, or ADSC-CM was tested as the main treatment. Eleven publications qualified: two studied nanofat, three, ADSC-CM, and six, SVF, either individually or in combination with other therapies. Only one randomized controlled trial (RCT) was found and classified as evidence 2b according to the Sackett scale. The rest were case-control studies or case series with small samples and no control, graded as evidence 3b and 4. A meta-analysis could not be conducted due to the heterogenicity of the study designs. Given the evidence obtained, Level D NICE recommendation was established. However, we consider that the positive findings are sufficiently consistent to support the elaboration of further RCTs that share criteria and methods.
雄激素性脱发(AGA)和斑秃(AA)是两种高度常见的病症,影响着各个年龄段的男性和女性,对他们的生活质量和自尊产生了强烈影响。尽管传统疗法的范围和疗效有限,但这两种病症都被认为是可逆的。需要专注于毛囊中发生的退行性变化的新治疗方法,以取得更好的效果。例如,脂肪来源的干细胞(ADSC)数量丰富且易于获取,在毛囊再生方面具有巨大潜力。ADSCs可以通过吸脂物的酶消化分离为基质血管成分(SVF),或者通过脂肪细胞的机械破碎分离为纳米脂肪。此外,ADSCs分泌组的条件培养基(ADSC条件培养基[CM])的商业制剂因其相对较低的成本和可及性已进入市场,成为一种有吸引力的替代方案。我们在PubMed Central和谷歌学术上进行了相关术语的交叉搜索。纳入标准是过去10年对患有AGA或AA的人类进行的研究,其中SVF、纳米脂肪或ADSC-CM被作为主要治疗方法进行测试。有11篇出版物符合条件:2篇研究纳米脂肪,3篇研究ADSC-CM,6篇研究SVF,这些研究可以单独进行,也可以与其他疗法联合进行。仅发现一项随机对照试验(RCT),根据Sackett量表分类为证据2b。其余的是病例对照研究或小样本且无对照的病例系列,分级为证据3b和4。由于研究设计的异质性,无法进行荟萃分析。根据获得的证据,制定了英国国家卫生与临床优化研究所(NICE)的D级推荐。然而,我们认为这些阳性结果足够一致,足以支持开展更多具有相同标准和方法的RCT。